William Blair Investment Management LLC Has $46.63 Million Holdings in Establishment Labs Holdings Inc. $ESTA

William Blair Investment Management LLC lessened its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 37.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 639,790 shares of the company’s stock after selling 377,753 shares during the period. William Blair Investment Management LLC’s holdings in Establishment Labs were worth $46,628,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Establishment Labs by 20.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock valued at $2,335,000 after buying an additional 9,557 shares during the period. Geode Capital Management LLC lifted its holdings in Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after buying an additional 299 shares during the period. WINTON GROUP Ltd acquired a new position in Establishment Labs in the second quarter valued at $651,000. Nebula Research & Development LLC lifted its holdings in Establishment Labs by 27.9% in the second quarter. Nebula Research & Development LLC now owns 16,214 shares of the company’s stock valued at $692,000 after buying an additional 3,538 shares during the period. Finally, Sei Investments Co. lifted its holdings in Establishment Labs by 13.3% in the second quarter. Sei Investments Co. now owns 48,428 shares of the company’s stock valued at $2,068,000 after buying an additional 5,668 shares during the period. Institutional investors and hedge funds own 72.91% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on ESTA. Stephens boosted their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a report on Wednesday, May 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. BTIG Research upped their price objective on shares of Establishment Labs from $88.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Wall Street Zen lowered shares of Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $87.14.

Establishment Labs Price Performance

Shares of NASDAQ ESTA opened at $72.19 on Monday. The firm’s 50-day moving average price is $64.59 and its 200-day moving average price is $68.08. Establishment Labs Holdings Inc. has a 1-year low of $33.35 and a 1-year high of $83.31. The firm has a market capitalization of $2.12 billion, a P/E ratio of -48.45 and a beta of 1.12. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.10). Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The company had revenue of $59.88 million for the quarter, compared to analyst estimates of $57.40 million. During the same quarter in the prior year, the company posted ($0.70) EPS. Establishment Labs’s revenue for the quarter was up 44.7% on a year-over-year basis. Equities research analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of Establishment Labs stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the transaction, the director owned 927,504 shares in the company, valued at approximately $69,952,351.68. The trade was a 10.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have sold 330,000 shares of company stock valued at $22,854,538. 9.99% of the stock is currently owned by company insiders.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.